BCHE and Alzheimer disease: At variance, the mDC levels in the AChEI-treated subgroup of AD were only slightly lower than those observed in HC, without any significant difference between them, suggesting that the anti-cholinesterase therapy may mitigate the blood mDC reduction observed in AD patients.